Joint Developments, Drug Recommendations, and Milestone Achievements Highlight the Strong Potential of Biotechnology - Research Report on Celgene, Onyx, Cytokinetics, Dendreon, and ChemoCentryx

Wed Jul 3, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

Joint Developments, Drug Recommendations, and Milestone Achievements Highlight the Strong Potential of Biotechnology - Research Report on Celgene, Onyx, Cytokinetics, Dendreon, and ChemoCentryx

PR Newswire

NEW YORK, July 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Cytokinetics, Incorporated (NASDAQ: CYTK), Dendreon Corp. (NASDAQ: DNDN), and ChemoCentryx, Inc. (NASDAQ: CCXI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celgene Corporation Research Report

On June 27, 2013, Celgene Corporation (Celgene) announced an agreement with MorphoSys AG to jointly develop MOR202 globally and to co-promote MOR202 in Europe. As per Celgene, MOR202 is a fully human monoclonal antibody targeting CD38 to treat patients with multiple myeloma (MM) and certain leukemias, and is currently being evaluated in a Phase 1/2a trial in patients with relapsed/refractory myeloma. Mark Alles, Executive Vice President and Global Head of Hematology and Oncology at Celgene, stated, "Strategic investments in next generation medical innovation make it possible for physicians to turn incurable cancers like multiple myeloma into chronic, more manageable diseases." Alles added, "This collaboration with MorphoSys enables us to rapidly advance a promising therapeutic antibody in a disease where significant progress is being made, but where patients continue to need new treatment options." The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/7541_CELG]

--

Onyx Pharmaceuticals, Inc. Research Report

On June 30, 2013, Onyx Pharmaceuticals, Inc. (Onyx) affirmed that it has received and also rejected an unsolicited proposal from Amgen Inc. (Amgen) for the acquisition of all its outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions. Dr. N. Anthony Coles, Chairman and CEO of Onyx, commented, "Onyx has tremendous momentum and, with the expansion of our pipeline and two successful product launches, the Company and our talented employees have created significant value for Onyx shareholders." Coles continued, "The Board and the management team remain focused on the opportunities in front of us, including the potential to expand the use of our existing therapies in different types of cancer and across different lines of therapy, as a result of several ongoing Phase 3 studies. We are actively exploring the potential to combine Onyx with another company as an option to create additional value for Onyx shareholders." The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/fcf8_ONXX]

--

Cytokinetics, Incorporated Research Report

On June 25, 2013, Cytokinetics, Incorporated (Cytokinetics) announced a collaboration with Astellas Pharma Inc. (Astellas) focused on the R&D and commercialization of skeletal muscle activators. Robert I. Blum, President and CEO of Cytokinetics, said, "Through this collaboration, we intend to jointly investigate the potential role that CK-2127107 and follow-on skeletal muscle activators can play in providing functional improvements in patients with diseases characterized by muscle weakness and fatigue. We are impressed with Astellas' strategic vision and capabilities in the areas of novel mechanism biopharmaceutical research and development." The Company stated that Astellas will have the exclusive rights to develop and commercialize drug candidates that may arise from these collaborative activities, subject to certain Cytokinetics' development and commercialization rights. The Full Research Report on Cytokinetics, Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/5a39_CYTK]

--

Dendreon Corp. Research Report

On June 28, 2013, Dendreon Corp. (Dendreon) announced that it has received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), which recommended that Provenge (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or Sipuleucel-T) be granted a marketing authorization in the European Union (EU). According to the Company, Provenge is to be used for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in male adults to whom chemotherapy is not yet clinically indicated. John H. Johnson, Dendreon's Chairman, President, and CEO, stated, "This recommendation represents a significant milestone for Dendreon as we advance the global market opportunity for Provenge. We are finalizing our plans for a capital-efficient launch in Europe, including evaluating our partnering options. We look forward to bringing the innovative treatment of PROVENGE to patients around the world." The Full Research Report on Dendreon Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/d202_DNDN]

--

ChemoCentryx, Inc. Research Report

On June 19, 2013, ChemoCentryx, Inc. (ChemoCentryx) announced that it has successfully completed its target enrollment of 270 patients in a Phase II clinical trial in diabetic nephropathy with CCX140, an inhibitor of the chemokine receptor known as CCR2 and the Company's lead wholly owned drug candidate. Thomas J. Schall, PhD, ChemoCentryx's President and CEO, said, "We are very pleased to have successfully completed this important Phase II enrollment milestone with an over-enrollment of patients in the study. This achievement will enable us to report 12-week data in approximately 200 patients in the third quarter of 2013, on track with our timeline projections." Schall added, "As our most advanced wholly owned program, CCX140 is a key component of the ChemoCentryx pipeline targeting high-value therapeutic areas with large unmet medical needs." The Full Research Report on ChemoCentryx, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/921e_CCXI]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.